Table 2.
Univariate Analysis of Risk Factors for PTLF After TACE.
| Variable | Patients with hepatic failure (n = 10, mean ± SD | Patients without hepatic failure (n = 32, mean ± SD | P value | OR | 95% CI |
|---|---|---|---|---|---|
| Age (years) | 63.20 ± 11.429 | 57.31 ± 10.965 | 0.155 | 1.057 | 0.979–1.140 |
| Mean Child score | 7.70 ± 1.252 | 6.25 ± 0.880 | 0.004 | 4.350 | 1.595–11.862 |
| Mean MELD score | 13.40 ± 2.757 | 8.38 ± 1.699 | 0.006 | 3.017 | 1.362–6.684 |
| Hb (g/dl) | 11.960 ± 2.453 | 11.960 ± 2.453 | 0.583 | 1.100 | 0.782–1.547 |
| Serum bilirubin (mg/dl) | 3.240 ± 1.070 | 1.328 ± 0.672 | 0.001 | 8.340 | 2.325–29.917 |
| SGOT (IU/L) | 68.90 ± 22.268 | 70.41 ± 55.723 | 0.932 | 0.999 | 0.985–1.014 |
| SGPT (IU/L) | 52.40 ± 23.448 | 41.91 ± 21.508 | 0.196 | 1.021 | 0.989–1.055 |
| Serum albumin (g/dl) | 2.640 ± 0.395 | 3.416 ± 0.386 | 0.005 | 0.002 | 0.000–0.150 |
| INR | 1.014 ± 0.082 | 1.120 ± 0.238 | 0.075 | 0.000 | 0.000–2.842 |
| AFP (ng/ml) | 110.023 ± 39.033 | 35.544 ± 31.128 | 0.003 | 1.062 | 1.021–1.104 |
| Serum creatinine (mg/dl) | 0.853 ± 0.098 | 0.738 ± 0.150 | 0.040 | 1.314 | −0.218–0.0119 |
| Mean tumor size (cm) | 11.790 ± 4.420 | 4.050 ± 2.309 | 0.001 | 1.754 | 1.248–2.464 |
| Number Of HCC lesions | 1.20 ± 0.422 | 1.09 ± 0.296 | 0.376 | 2.417 | 0.343–17.036 |
| HVPG (mm Hg) | 16.50 ± 4.275 | 12.66 ± 4.426 | 0.035 | 1.251 | 1.016–1.541 |
| ICG (R15) | 38.950 ± 6.698 | 18.48 ± 8.37 | 0.002 | 1.448 | 1.117–1.006 |
CI, confidence interval; MELD, Model for End-Stage Liver Disease; HCC, hepatocellular carcinoma; HVPG, hepatic venous pressure gradient; ICG, indocyanine green; OR, odds ratio; PTLF, post-TACE liver failure.